Nelson Advisors: What Strategic Acquirers Actually Pay For - Five Case Studies Deconstructing 5 Recent HealthTech Deal Structures
A composite, anonymised breakdown of earn outs, escrow, and valuation mechanics — for founders preparing to sell and buy side teams structuring the next deal.
A note before we start: the five deal profiles below are anonymised composites, built to be representative of structural patterns we see repeatedly across lower to mid market HealthTech M&A, not disclosures of specific client transactions or identifiable named deals.
The headline multiples, earn out mechanics and escrow terms reflect real market conventions (grounded in published 2025-2026 deal term data), reassembled into illustrative scenarios so the structural lessons can be discussed openly without breaching anyone's confidentiality. If you've been through a process that rhymes with one of these, that's the point, these are patterns, not case files.
Every founder who has run a sale process has had some version of the same jarring realisation: the number on the front page of the press release and the number that eventually lands in the bank account are frequently not the same number, and the gap between them is entirely a function of deal structure. Headline enterprise value tells you almost nothing about what a seller actually walks away with, or what a buyer is actually protected against, until you look underneath it, at how much is cash at close, how much sits in escrow, how much is contingent on an earn out that may or may not pay out, and how the working capital adjustment gets calculated on the way out the door.
This matters more in HealthTech than in most sectors, because HealthTech deals carry a specific set of structural risks that generic M&A playbooks don't fully account for, regulatory exposure that takes months to surface, payer and reimbursement dynamics that can shift the revenue base after signing, clinical or technical validation that hasn't fully played out and retention risk on the specialised technical and clinical talent that often is the acquisition. Strategic acquirers structure around those risks deliberately.
Understanding how they do it and why, is the single most useful thing a founder can learn before entering a process, and the single most useful discipline a buy-side team can sharpen before making an offer.
We'll walk through five composite deal structures spanning the sub sectors where most mid market HealthTech M&A activity actually happens, AI-enabled revenue cycle management, value based care, legacy SaaS, MedTech hardware and early-stage AI diagnostics and use each one to unpack a different structural lesson: how earn outs get built, when escrow gets replaced by insurance, how working capital pegs quietly redistribute value, and what a regulatory gate does to a deal timeline.
The State of Deal Structure in 2026: What the Data Actually Shows
Before the case studies, it's worth grounding this in the aggregate numbers, because founder intuition about "normal" deal terms is frequently calibrated to a handful of anecdotes rather than the actual base rates. Recent deal-term studies covering the 2025 private-target M&A market (the kind of data aggregators like SRS Acquiom compile from actual closed transactions) paint a consistent picture.
Earn outs appear in roughly a quarter of non-life-sciences private-target deals, about 24% in the most recent full-year study, which means the majority of deals still close on a clean cash and stock basis. But that aggregate figure understates how concentrated earnout usage is in categories exactly like HealthTech, where future performance genuinely does hinge on variables the buyer can't fully underwrite at signing: provider or clinician retention, payer contract renewals, reimbursement rate stability, or continued adoption of a newly-integrated AI feature.
When an earn out is used, the payout data is sobering for sellers who assume they'll collect the full contingent amount: across all earn out deals, only a little over half see any payout at all, and the dollar-weighted average payout lands around 50 cents on the dollar for deals that pay something, but drops to roughly 21 cents on the dollar once you include the earn outs that pay nothing at all. In life sciences and biotech specifically, where earnouts are often milestone based across multi-year clinical or regulatory timelines, that average payout falls closer to 19 cents on the dollar. The lesson embedded in that data is blunt: an earnout is not a discount on today's price that you're likely to collect later. Structurally, most earn out dollars simply never get paid.
Escrow and holdback arrangements remain close to universal, roughly 88% of private-target deals in the most recent study included one, which tells you that despite years of seller friendly market commentary, buyers have not meaningfully given up their primary post-closing protection mechanism. What has changed is what sits alongside escrow: representations and warranties insurance (RWI) now appears in close to half of deals studied (around 46%) and where it's used, it typically allows the seller to negotiate a materially smaller escrow, since the insurer, not the seller's own proceeds, becomes the primary source of recovery for most breach claims.
Working capital adjustments, meanwhile, are getting more bespoke rather than more standardised: nearly 40% of deals now use a detailed "worksheet approach" tailored to the target's specific balance sheet, rather than a generic net working capital peg, which matters enormously in healthcare, where aged receivables, payer disputes, and provider compensation timing can swing the true working capital position by a wide margin if the mechanism isn't built carefully.
With that grounding, here's the framework we'll apply to each of the five case studies: the headline valuation and multiple; the split between cash at close and contingent consideration; how the earn out (where present) is structured and metered; how escrow, indemnity and RWI interact; how the working capital mechanism was built; and, most importantly, what the structure actually reveals about what the buyer believed they were paying for.
Case Study 1: The AI Native Revenue Cycle Management Platform
The business: A mid-market RCM technology platform that had layered AI driven denial prediction and prior-authorisation automation on top of a traditional claims workflow product, growing ARR into the high-$20M range with strong net revenue retention among mid-sized health system customers.
The buyer: A larger, strategically adjacent RCM consolidator looking to acquire the AI capability rather than build it internally, and to cross-sell it into its own much larger existing customer base.
Headline structure: Enterprise value landed toward the upper end of the AI-enabled platform range, reflecting the well-documented premium (commonly cited at 20-30%) that AI-native revenue cycle assets command over non AI peers, but only around 65% of that value was paid in cash at close. The remaining roughly 35% was structured as a two-year earn out tied to two specific, buyer controllable-adjacent metrics: net revenue retention of the acquired customer base above a defined floor, and a cross-sell attach rate measuring how many of the acquirer's existing customers adopted the AI module within the earn out window.
Why this structure: The buyer was not primarily worried about whether the technology worked, the technical diligence had validated that. It was worried about two things a price alone can't de-risk: whether the AI capability would retain its edge and its customers once integrated into a larger, less nimble organisation, and whether the acquirer's own sales motion would actually succeed in cross-selling it. Structuring the earn out around cross-sell attach rate, in particular, put a portion of the seller's upside directly on the hook for the acquirer's own execution, which is exactly the kind of earn out term sell side counsel should push back on hard, since it ties seller proceeds to a variable the seller doesn't control post-closing.
Escrow and RWI: Given the earnout already created a meaningful holdback of value, the deal used RWI to cover general representations, reducing the escrow specifically tied to fundamental and tax representations to a modest single-digit percentage of the cash consideration, held for twelve months. The earn out itself effectively functioned as a second, larger and longer duration security blanket for the buyer, a pattern increasingly common in AI enabled HealthTech deals, where buyers use the earn out to do double duty as both a valuation bridge and a retention mechanism, on top of standard escrow.
The lesson: When an earn out metric depends partly on the buyer's own post close execution, that's a specific, negotiable red flag, not a boilerplate term. Founders should push either for metrics they fully control (their own product's retention, not the buyer's cross-sell success) or for minimum-effort covenants obligating the buyer to actually invest in achieving the shared metric.
Case Study 2: The Value Based Care Platform Bolt-On
The business: A value-based care enablement platform supporting risk-bearing primary care groups, generating revenue through a mix of PMPM technology fees and a smaller shared-savings component tied to downstream medical cost performance.
The buyer: A private-equity-backed platform actively rolling up value based care technology and services assets, structuring this as a bolt-on to an existing portfolio company.
Headline structure: Valued within the sector's typical mid-single-digit EV/Revenue range with a supportive EV/EBITDA multiple, but structured with a meaningful rollover component, the founder and two other executives rolled roughly 20% of their proceeds into equity in the PE platform's NewCo, rather than taking full cash consideration. The remaining consideration split roughly 75% cash at close and 25% EBITDA-based earn out over an 18-month window.
Why this structure: Value based care economics have an inherent lag problem, shared savings performance often isn't fully knowable for 12-18 months after a given plan year closes, because claims run out slowly. An EBITDA earn out tied to that period let the buyer avoid overpaying for savings performance that hadn't yet been realised or verified, while the rollover equity gave the buyer confidence that the founding team's incentives stayed aligned with the platform's success post-close, a structure PE buy and build platforms lean on heavily specifically because they need the founding operator to keep running the business well after signing, not just hand over the keys.
Escrow and indemnity: This is where value-based care and other regulated-reimbursement HealthTech deals diverge sharply from a typical SaaS transaction. Alongside the standard escrow, the buyer negotiated a separate, longer-duration indemnity holdback specifically earmarked for healthcare regulatory exposure, Stark Law, Anti-Kickback Statute, and payer contract compliance, held for 24 months rather than the customary 12, reflecting how long those specific liabilities typically take to surface. RWI was discussed but ultimately not used for the healthcare-regulatory representations specifically, since insurers price that coverage expensively (or decline it outright) for businesses with meaningful shared savings or risk-based reimbursement exposure, a useful data point for any value-based care founder assuming RWI will let them avoid escrow entirely.
The lesson: Regulatory and reimbursement risk in value-based care doesn't get priced away by a strong multiple, it gets structurally quarantined into a longer, dedicated indemnity period. Founders in this sub-sector should expect and plan for that rather than treating it as a red flag specific to their business.
Case Study 3: The Legacy HealthTech SaaS Company — A Compressed Multiple Exit
The business: A well-run, profitable clinical workflow SaaS company with a stable but slow-growing customer base, minimal AI differentiation, and healthy but unspectacular gross margins, the kind of "good, boring" business that used to command a premium multiple in 2021 and now sits at the more compressed end of the legacy SaaS range.
The buyer: A strategic acquirer consolidating point solutions into a broader clinical operations suite, primarily interested in the customer base and integration rather than the technology itself.
Headline structure: EV/Revenue landed toward the lower end of the legacy SaaS band, reflecting the market's broader multiple compression and the absence of an AI premium. Almost the entire consideration, over 90%, was cash at close, with no earn out at all. On its face, this looks like the "cleanest" of the five structures.
Why this structure: With a mature, predictable, unexciting but reliable revenue base and no growth story to underwrite, the buyer had little reason to defer consideration through an earn out, there was no meaningful uncertainty about future performance to bridge, because there was no meaningful growth being priced in to begin with. This is a genuinely important and under-discussed pattern: earnouts are not primarily a tool buyers use to punish sellers; they're a tool used to price uncertainty. A flat, predictable business with a lower multiple often gets a cleaner, more cash heavy structure than a higher-multiple, higher-growth business, because there's simply less for the buyer to hedge against.
Escrow and working capital: This is where the real friction showed up. The deal used a standard 12-month escrow at a conventional percentage of purchase price, nothing unusual there, but the working capital adjustment used a detailed worksheet approach rather than a simple peg, and it specifically excluded a category of aged accounts receivable the seller had been carrying as collectible.
The post closing true-up ultimately reduced the seller's proceeds by a low to mid single digit percentage of the headline price, not because anything was misrepresented, but because the mechanism for calculating "normal" working capital was negotiated in the buyer's favour during diligence, when the seller's team was focused on defending the multiple rather than scrutinising the working capital definition.
The lesson: A clean, all cash, no earn out headline is not automatically the best negotiated structure. Founders (and their advisors) need to spend as much diligence energy on the working capital mechanism as on the price, it is, in practice, where a meaningful amount of value quietly changes hands in otherwise "simple" deals.
Case Study 4: The MedTech Hardware Company — A Regulatory-Gated Sale
The business: A diagnostic device manufacturer with a strong installed base in several European markets, mid single digit revenue growth, and a product line that was mid process through EU MDR recertification at the time of the sale.
The buyer: A larger strategic MedTech acquirer looking to add the device line to its distribution network, with a particular interest in the installed base and the regulatory pathway already underway.
Headline structure: Priced within the MedTech hardware EV/Revenue and EV/EBITDA bands, but with a specific, binary structural feature layered on top: a defined portion of consideration, roughly 15% of total enterprise value, was held in a dedicated regulatory escrow, contingent specifically on the completion of EU MDR/IVDR certification within an 18 to 24 month window following closing, separate from the standard indemnity escrow.
Why this structure: In MedTech, regulatory certification isn't a diligence item you can fully close out before signing, for a company mid recertification, it's a genuinely binary future event with a real chance of delay or, in a worst case, non-approval. Rather than trying to price that uncertainty into the multiple (which sellers would resist, since it discounts value for a risk they believe is low) or walk away from the deal until certification completed (which both sides had commercial reasons to avoid), the parties isolated the specific risk into its own contingent bucket. This is a structurally cleaner solution than folding regulatory risk into a generic indemnity, because it ties the holdback precisely to the actual event of concern rather than to a broad, hard-to-quantify representation.
Escrow and RWI: Standard indemnity escrow and RWI were used for the general representations, at conventional market terms, the regulatory certification holdback sat entirely separate from and in addition to, that standard structure. Buyers in regulated-device deals increasingly treat certification status as its own line item rather than trying to shoehorn it into representations and warranties language and RWI insurers are typically unwilling to underwrite binary regulatory approval risk at all, which is exactly why this had to be solved structurally rather than through insurance.
The lesson: When a real, foreseeable, binary event sits between signing and full value realisation, a regulatory clearance, a major contract renewal decision, a pending litigation outcome, the cleanest structural answer is often a dedicated, narrowly defined holdback tied to that specific event, not a broader earnout or an inflated general escrow. It's more negotiable, more transparent and easier for both sides to model.
Case Study 5: The Early Stage AI Diagnostics Company — An Acquihire-Plus-Milestone Structure
The business: A venture-backed, pre-commercial-scale AI diagnostics company with genuinely differentiated technology and a small but highly specialised technical and clinical team, but limited revenue and a runway problem that made an independent path to Series B increasingly uncertain.
The buyer: A larger diagnostics or pharma-adjacent strategic acquirer primarily interested in the technology and, critically, the team that built it.
Headline structure: A modest headline enterprise value relative to the company's prior venture valuation, reflecting both limited commercial traction and the reality that acquihire-style deals rarely price at growth-stage multiples, with the majority of total consideration, well over half, structured as retention-linked payments and milestone-based earn out rather than upfront cash. A meaningful portion of total deal value was allocated directly to employment agreements and retention bonuses for named key technical staff, vesting over a multi-year period contingent on continued employment.
Why this structure: For the buyer, the asset being acquired wasn't primarily the existing revenue or even the IP in isolation, it was the specific team's ability to keep developing the technology inside the acquirer's infrastructure and regulatory apparatus. Structuring the bulk of value as retention contingent and milestone, contingent consideration is the buyer's way of paying for continued execution rather than for a balance sheet, and it's a completely standard pattern in early-stage technical acquisitions across HealthTech, not a sign of a "bad" deal.
Escrow and the earn out reality: Given the broader data point cited earlier, that earn outs across the market pay out at an average of only about 21 cents on the dollar once non-paying deals are included and considerably less in life-sciences-adjacent categories, the founding team in this scenario negotiated hard for milestone definitions that were technical and objectively measurable (a specific validation study readout, a specific integration milestone) rather than commercial or revenue-based, precisely because commercial milestones in a newly-acquired, newly-integrated business are far more exposed to factors outside the founding team's control. They also negotiated acceleration provisions that vested a portion of the retention consideration immediately upon an involuntary termination without cause, protecting the team against the scenario where the acquirer simply decided, eighteen months in, that the integration wasn't a priority anymore.
The lesson: In acquihire and milestone structures, the earn out payout statistics should weigh heavily on how founders negotiate the milestone definitions themselves. Objective, technical, founder controlled milestones with acceleration on termination protection are worth fighting for far more than a marginally higher headline number with vague, buyer-dependent, or commercially-defined triggers.
What These Five Structures Have in Common
Looking across all five, a few patterns hold regardless of sub-sector, and they're worth stating plainly for both sides of the table.
For sell side founders, the single most important discipline is distinguishing headline value from realisable value before you get emotionally anchored to a number. An earn out is not a lower-conviction version of cash, historically, it pays out in full far less often than founders assume and the metrics attached to it deserve the same scrutiny as the price itself.
Push hard for earn out metrics you actually control, resist metrics that depend on the buyer's own post-close execution, and treat the working capital mechanism with the same seriousness as the multiple, since it is routinely where value quietly moves in deals that look "clean" on the surface. Where RWI is available and priced reasonably, it is very often worth trading a slightly lower headline number for a smaller escrow and faster access to your proceeds, but understand that healthcare regulatory risk specifically is often excluded or priced prohibitively by insurers, which is why dedicated regulatory holdbacks remain common in this sector even as RWI adoption grows elsewhere.
For buy-side PE and VC teams, the lesson runs the other direction: earn outs and holdbacks are tools for aligning incentives and bridging genuine uncertainty, not just mechanisms for extracting a discount. A well structured earn out tied to metrics the seller genuinely controls does more to protect deal value than an aggressively low headline price ever will, and a regulatory or compliance holdback that's precisely scoped to the actual risk in question is both more defensible in negotiation and more effective at doing its job than a generic, oversized general escrow.
Diligence preparedness cuts both ways here too, a target that walks into a process with clean, organised, audit-ready materials on the specific risk areas a buyer will focus on (working capital detail, payer contract status, regulatory certification timelines, key employee agreements) earns materially better structural terms than one that makes the buyer's team dig for answers, because uncertainty is exactly what buyers price into structure when they can't price it into diligence.
The through line across all five composites is this: in HealthTech M&A, structure is where risk actually gets allocated, and the headline multiple is, at best, half the story. Founders who understand that going into a process negotiate meaningfully better outcomes than founders who focus exclusively on defending the number on the front page and buy side teams who structure deliberately around real risk, rather than defaulting to boilerplate, close cleaner deals with fewer post-signing disputes.
If you're preparing for a sale process, or building a thesis around bolt-on acquisitions in HealthTech and want to pressure-test how a specific deal structure would actually allocate risk and proceeds between buyer and seller, that's exactly the kind of conversation Nelson Advisors has with clients on both sides of the table before terms get locked in.
Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
Comments